STORM Therapeutics Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 33

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $32.1M

  • Investors
  • 10

STORM Therapeutics General Information

Description

Developer of small molecule inhibitors of RNA-modifying enzymes designed for the treatment of cancer. The company tackles diseases through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases, providing physicians with first-in-class therapies against RNA epigenetic targets.

Contact Information

Formerly Known As
Iceni Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Babraham Research Campus
  • Moneta Building
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223 000000

STORM Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

STORM Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 08-Jun-2022 $32.1M 000.00 000.00 Completed Generating Revenue
5. Later Stage VC (Series B) 25-May-2021 Cancelled Pre-Clinical Trials
4. Early Stage VC (Series A) 20-May-2019 000.00 0000 000.00 Completed Pre-Clinical Trials
3. Early Stage VC 22-Dec-2017 000.00 000.00 000.00 Completed Startup
2. Early Stage VC 07-May-2015 $301K $1.05M Completed Startup
1. Seed Round 01-May-2015 $748K $748K Completed Startup
To view STORM Therapeutics’s complete valuation and funding history, request access »

STORM Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B2 Preferred 00,000,000 00.000000 00.00 00.00 00.00 00.000
B1 Preferred 00,000,000 00.000000 00.00 00.00 00.00 00.000
A1 Preferred 00,000,000 00.000000 00.00 00.00 00.00 00.00
A Preferred 3,000,000 $0.000125 $1.66 $1.66 $1.66 5.74%
A Preferred 12,645,174 $0.000125 $1.25 $1.25 $1.25 24.21%
To view STORM Therapeutics’s complete cap table history, request access »

STORM Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of small molecule inhibitors of RNA-modifying enzymes designed for the treatment of cancer. The company tackle
Drug Discovery
Cambridge, United Kingdom
33 As of 2022
000.00
00.00 0000-00-00
0000000000 0 000.00

0 0000

or incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation u
000000000000000
Houston, TX
0 As of 0000
00.00
0000000000 00.00

0000 0

do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostru
0000 000000000
London, United Kingdom
00 As of 0000
00000
0000 0000-00-00
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

STORM Therapeutics Competitors (60)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
7 Hills Pharma Venture Capital-Backed Houston, TX 0 00.00 0000000000 00.00
0000 000000000000 Venture Capital-Backed London, United Kingdom 00 00000 0000000000 0 00000
00000000 Formerly VC-backed Tubingen, Germany 000 00000 000000000 00000
0000000 000 Corporation New York, NY 000 00000 0000000000 00000
0000000 0000000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
You’re viewing 5 of 60 competitors. Get the full list »

STORM Therapeutics Patents

STORM Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202107909-D0 Inhibitory compounds Pending 02-Jun-2021
GB-202107907-D0 Combination therapies Pending 02-Jun-2021
GB-202107905-D0 Processes for the preparation of inhibitory compounds Pending 02-Jun-2021
GB-202107783-D0 Inhibitory compounds Pending 01-Jun-2021
GB-202015985-D0 Inhibitory compounds Inactive 08-Oct-2020
To view STORM Therapeutics’s complete patent history, request access »

STORM Therapeutics Executive Team (7)

Name Title Board Seat Contact Info
Oliver Rausch Ph.D Chief Scientific Officer
Eric Miska Ph.D Co-Founder & Board Member
Tony Kouzarides Ph.D Co-Founder & Board Member
Wesley Blackaby Ph.D Vice President Chemistry
Josefin-Beate Holz Chief Medical Officer & Clinical Advisor
You’re viewing 5 of 7 executive team members. Get the full list »

STORM Therapeutics Board Members (17)

Name Representing Role Since
Bruno Montanari Ph.D Seroba Life Sciences Board Observer 000 0000
Christopher O'Donnell Ph.D Self Board Member 000 0000
Eric Miska Ph.D STORM Therapeutics Co-Founder & Board Member 000 0000
Hakan Goker Ph.D M Ventures Board Member 000 0000
John Haurum Ph.D Self Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

STORM Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

STORM Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fast Track Initiative Venture Capital Minority 000 0000 000000 0
Cambridge Enterprise Venture Capital Minority 000 0000 000000 0
Cancer Research Horizons Venture Capital Minority 000 0000 000000 0
IP Group Venture Capital Minority 000 0000 000000 0
M Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »